BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29247691)

  • 1. Single dose HBsAg CS-γ-PGA nanogels induce potent protective immune responses against HBV infection.
    Wang H; Han Q; Zhao H; Xu D; Zhang J
    Eur J Pharm Biopharm; 2018 Mar; 124():82-88. PubMed ID: 29247691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity.
    Lugade AA; Bharali DJ; Pradhan V; Elkin G; Mousa SA; Thanavala Y
    Nanomedicine; 2013 Oct; 9(7):923-34. PubMed ID: 23542018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
    Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
    Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model.
    Mahdavi M; Mavandadnejad F; Yazdi MH; Faghfuri E; Hashemi H; Homayouni-Oreh S; Farhoudi R; Shahverdi AR
    J Infect Public Health; 2017; 10(1):102-109. PubMed ID: 27026241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV.
    Zhao H; Wang H; Hu Y; Xu D; Yin C; Han Q; Zhang J
    Int J Nanomedicine; 2021; 16():4913-4928. PubMed ID: 34321879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycation-decorated PLA microspheres induce robust immune responses via commonly used parenteral administration routes.
    Chen X; Wang L; Liu Q; Jia J; Liu Y; Zhang W; Ma G; Su Z
    Int Immunopharmacol; 2014 Dec; 23(2):592-602. PubMed ID: 25466267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
    Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
    Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemokinin-1 as an adjuvant molecule enhancing humoral and memory responses to HBsAg DNA vaccination.
    Chen X; Zhang W; Gao W; Zou Q; Feng C; Liu H; Zhou C; Zhang Y; Wang B
    Viral Immunol; 2012 Aug; 25(4):289-96. PubMed ID: 22876773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg].
    Du X; Wang J; Kang Y; Xiao W; Zhao G; Wang B
    Wei Sheng Wu Xue Bao; 2009 Jul; 49(7):938-42. PubMed ID: 19873759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response.
    Pawar D; Jaganathan KS
    Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
    Ito H; Ando T; Nakamura M; Ishida H; Kanbe A; Kobiyama K; Yamamoto T; Ishii KJ; Hara A; Seishima M; Ishikawa T
    J Viral Hepat; 2017 Feb; 24(2):155-162. PubMed ID: 27807909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
    Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
    Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of hepatitis B vaccination program in upper Egypt: Flow cytometry and the evaluation of long term immunogenicity.
    Makhlouf NA; Farghaly AM; Zaky S; Rashed HA; Abu Faddan NH; Sayed D; El-Badawy O; Afifi N; Hamza WS; El-Sayed Y
    J Med Virol; 2016 Sep; 88(9):1567-75. PubMed ID: 26910304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination.
    Zhu CL; Liu P; Chen T; Ni Z; Lu LL; Huang F; Lu J; Sun Z; Qu C
    Vaccine; 2011 Oct; 29(44):7835-41. PubMed ID: 21816197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.